Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities

Zita-Rose Manjaly Thomas; Anne Leuppi-Taegtmeyer; Dagmar Jamiolkowski; Esther Steveling-Klein; Felicitas Bellutti-Enders; Kathrin Scherer Hofmeier; Karin Hartmann

doi:10.1016/j.jaci.2020.07.008

Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities

J Allergy Clin Immunol. 2020 Oct;146(4):786-789. doi: 10.1016/j.jaci.2020.07.008. Epub 2020 Jul 22.

Authors

Zita-Rose Manjaly Thomas¹, Anne Leuppi-Taegtmeyer², Dagmar Jamiolkowski³, Esther Steveling-Klein¹, Felicitas Bellutti-Enders⁴, Kathrin Scherer Hofmeier¹, Karin Hartmann⁵

Affiliations

¹ Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
² Regional Pharmacovigilance Centre, Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland; Department of Pharmaceutical Sciences, University Hospital Basel, Basel, Switzerland.
³ Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.
⁴ Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland; Allergy Unit, University Children's Hospital Basel, Basel, Switzerland.
⁵ Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland. Electronic address: [email protected].

No abstract available

Keywords: Acute respiratory syndrome; COVID-19; SARS-CoV-2; adverse drug reactions; coronavirus; drug allergy; drug hypersensitivity; remdesivir.

Publication types

Editorial
Review

MeSH terms

Adenosine Monophosphate / administration & dosage
Adenosine Monophosphate / adverse effects
Adenosine Monophosphate / analogs & derivatives
Adrenal Cortex Hormones / therapeutic use
Alanine / administration & dosage
Alanine / adverse effects
Alanine / analogs & derivatives
Amides / administration & dosage
Amides / adverse effects
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Antiviral Agents / administration & dosage
Antiviral Agents / adverse effects*
Betacoronavirus / drug effects
Betacoronavirus / immunology
Betacoronavirus / pathogenicity
COVID-19
Coronavirus Infections / drug therapy*
Coronavirus Infections / immunology
Coronavirus Infections / virology
Cytokine Release Syndrome / immunology
Cytokine Release Syndrome / prevention & control*
Cytokine Release Syndrome / virology
Drug Hypersensitivity / diagnosis
Drug Hypersensitivity / drug therapy
Drug Hypersensitivity / etiology*
Drug Hypersensitivity / immunology
Humans
Immunity, Innate / drug effects
Immunologic Factors / administration & dosage
Immunologic Factors / adverse effects*
Indoles / administration & dosage
Indoles / adverse effects
Infliximab / administration & dosage
Infliximab / adverse effects
Interleukin 1 Receptor Antagonist Protein / administration & dosage
Interleukin 1 Receptor Antagonist Protein / adverse effects
Nitriles
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / immunology
Pneumonia, Viral / virology
Pyrazines / administration & dosage
Pyrazines / adverse effects
Pyrazoles / administration & dosage
Pyrazoles / adverse effects
Pyrimidines
SARS-CoV-2
Severity of Illness Index

Substances

Adrenal Cortex Hormones
Amides
Antibodies, Monoclonal, Humanized
Antiviral Agents
Immunologic Factors
Indoles
Interleukin 1 Receptor Antagonist Protein
Nitriles
Pyrazines
Pyrazoles
Pyrimidines
remdesivir
Adenosine Monophosphate
ruxolitinib
umifenovir
Infliximab
favipiravir
tocilizumab
sarilumab
Alanine